In about 30% of human lung cancer cases, mutations arise in either KEAP1 or NRF2 (encoded by Nfe2l2), leading to NRF2 stabilizing and the modulation of oxidative homeostasis.[254] However, the accumulation of NRF2 in lung cancer induces HO‐1, an enzyme catalyzing heme degradation, leading to the stabilization of BACH1, which subsequently facilitates the metastasis of lung adenocarcinoma (LUAD). The gene discussed is NFE2L2; the disease is lung cancer.